DrugDashboards

Insulin glargine

Insulin glargine · INSULIN GLARGINE 100 U/mL · Injection, Solution · Eli Lilly Italia SPA

NDC 54568-0766-10 · 1 BOX in 1 BOX / 30 BOX in 1 BOX / 330 CARTRIDGE in 1 BOX / 3 mL in 1 CARTRIDGE · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for insulin glargine (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
—
TE code
—
Approval date
—
Patents / exclusivity
—

Shortage history

  • Planned discontinuation — Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)Oct 24, 2025

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Insulin glargine (Injection, Solution)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsINSULIN GLARGINE 100 [iU]/mLJul 15, 2026Sep 3, 2026
Eli Lilly and CompanyINSULIN GLARGINE 100 [iU]/mLJul 15, 2026Sep 3, 2026
Sanofi-Aventis U.S. LLCINSULIN GLARGINE 300 U/mLJul 15, 2026Sep 3, 2026
Eli Lilly Italia SPAINSULIN GLARGINE 100 U/mLJul 15, 2026Sep 2, 2026
Lilly FranceINSULIN GLARGINE 100 U/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsINSULIN GLARGINE 300 U/mLJul 15, 2026Aug 31, 2026
Sanofi-Aventis U.S. LLCINSULIN GLARGINE 300 [iU]/mLJul 15, 2026Aug 31, 2026
sanofi-aventis U.S. LLCINSULIN GLARGINE 100 [iU]/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Insulin glargine — NDC 54568-0766-10," retrieved September 3, 2026, https://drugdashboards.com/drug/54568076610.

Free to cite with attribution — see how the data is put together.